Merck and Pfizer's Phase III JAVELIN head and neck 100 study to be terminated

16 March 2020
bavencio_merck_large

EMD Serono, the biopharmaceutical business of Germany’s Merck KGaA (MRK: DE), and Pfizer (NYSE: PFE) today announced a disappointing update from the Phase III JAVELIN head and neck 100 study evaluatingBavencio (avelumab) in addition to chemoradiotherapy (CRT) versus standard-of-care CRT in patients with untreated locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

Already-approved Bavencio has previously failed in the Phase III JAVELIN Gastric 100 study and the Phase III JAVELIN Ovarian PARP 100 study.

Merck’s shares were down 9.7% at 82.44 euros by early afternoon trading, but that was against a background of plunging markets caused by the coronavirus and other factors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology